Trending Stock News

Pentwater Capital Management LP Trimmed Esperion Therapeutics (ESPR) Position By $20.41 Million; Driehaus Capital Management Has Lowered Exact Sciences (EXAS) Holding By $3.16 Million

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Pentwater Capital Management Lp decreased Esperion Therapeutics Inc (ESPR) stake by 14% reported in 2017Q4 SEC filing. Pentwater Capital Management Lp sold 313,969 shares as Esperion Therapeutics Inc (ESPR)’s stock rose 22.41%. The Pentwater Capital Management Lp holds 1.93M shares with $127.02 million value, down from 2.24 million last quarter. Esperion Therapeutics Inc now has $1.96 billion valuation. The stock decreased 0.17% or $0.12 during the last trading session, reaching $73.14. About 14,549 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 24, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Driehaus Capital Management Llc decreased Exact Sciences Corp (EXAS) stake by 51.15% reported in 2017Q4 SEC filing. Driehaus Capital Management Llc sold 60,740 shares as Exact Sciences Corp (EXAS)’s stock declined 19.82%. The Driehaus Capital Management Llc holds 58,008 shares with $3.05 million value, down from 118,748 last quarter. Exact Sciences Corp now has $5.96 billion valuation. The stock increased 1.25% or $0.61 during the last trading session, reaching $49.31. About 279,211 shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 81.43% since April 24, 2017 and is uptrending. It has outperformed by 69.88% the S&P500.

Investors sentiment decreased to 1.33 in Q4 2017. Its down 0.34, from 1.67 in 2017Q3. It worsened, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Quantitative Investment Mgmt Limited Company holds 0.02% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 17,000 shares. Citadel Lc accumulated 173,692 shares. Creative Planning holds 0% or 4,776 shares in its portfolio. Quantbot Tech LP has invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Partner LP holds 12,140 shares or 0.92% of its portfolio. D E Shaw & Co invested in 0% or 10,456 shares. The New York-based Ghost Tree Limited Liability Corporation has invested 3.55% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Parkside Bancorp invested in 900 shares. Meeder Asset Mngmt Inc accumulated 371 shares or 0% of the stock. 4,841 were reported by Group Inc One Trading L P. Meditor Gru Ltd stated it has 19.68% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Dimensional Fund Advisors Limited Partnership has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Illinois-based Northern Corporation has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 70 were reported by North Star Inv Management Corporation. New York State Common Retirement Fund reported 70,272 shares stake.

Pentwater Capital Management Lp increased Allergan Plc (Call) stake by 10,000 shares to 360,000 valued at $58.89M in 2017Q4. It also upped Monsanto Co (NYSE:MON) stake by 2.58 million shares and now owns 8.78 million shares. Qualcomm Inc (Put) was raised too.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on May, 3. They expect $-1.56 earnings per share, up 13.33% or $0.24 from last year’s $-1.8 per share. After $-1.44 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 8.33% negative EPS growth.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 62 analyst reports since July 28, 2015 according to SRatingsIntel. On Friday, August 7 the stock rating was maintained by Chardan Capital Markets with “Sell”. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Wednesday, October 18 by Needham. The firm has “Buy” rating by Jefferies given on Wednesday, August 9. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Hold” rating given on Monday, January 22 by Citigroup. Jefferies maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, March 19 with “Buy” rating. The company was upgraded on Monday, August 10 by Needham. The firm has “Neutral” rating given on Friday, February 26 by Chardan Capital Markets. Chardan Capital Markets maintained it with “Sell” rating and $40 target in Monday, July 27 report. The firm has “Buy” rating by Needham given on Thursday, June 30. Needham maintained the shares of ESPR in report on Monday, March 20 with “Strong Buy” rating.

Investors sentiment decreased to 0.88 in 2017 Q4. Its down 0.13, from 1.01 in 2017Q3. It turned negative, as 25 investors sold EXAS shares while 105 reduced holdings. 44 funds opened positions while 70 raised stakes. 92.48 million shares or 1.24% less from 93.65 million shares in 2017Q3 were reported. Royal Comml Bank Of Canada has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Advisory Rech invested in 0.07% or 81,914 shares. Doheny Asset Mngmt Ca owns 1.09% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 44,640 shares. Ubs Asset Mgmt Americas Inc has invested 0.04% in Exact Sciences Corporation (NASDAQ:EXAS). Tiaa Cref Mgmt Limited Liability Company invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Axa invested in 131,500 shares. Financial Advisory Service holds 0.11% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 8,000 shares. Amer Natl Tx reported 0.44% in Exact Sciences Corporation (NASDAQ:EXAS). Voya Invest stated it has 0.18% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Qs Investors Llc accumulated 2,563 shares. Acadian Asset Management Lc stated it has 153 shares. Salem Invest Counselors invested in 0.04% or 6,480 shares. 2,940 were accumulated by Meeder Asset Management. Ww Asset Mgmt Inc owns 0.01% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 4,286 shares. Metropolitan Life Ins Comm has 36,687 shares.

Driehaus Capital Management Llc increased Nxp Semiconductors Nv (NASDAQ:NXPI) stake by 53,117 shares to 666,598 valued at $78.05M in 2017Q4. It also upped Ingevity Corp stake by 5,656 shares and now owns 29,046 shares. Everbridge Inc was raised too.

Since January 2, 2018, it had 0 buys, and 20 insider sales for $24.73 million activity. ARORA MANEESH sold $276,367 worth of stock. $325,440 worth of Exact Sciences Corporation (NASDAQ:EXAS) shares were sold by Zanotti Katherine S. LIDGARD GRAHAM PETER sold $1.11 million worth of stock. $5.58 million worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by Conroy Kevin T. 2,122 shares valued at $85,124 were sold by COWARD D SCOTT on Saturday, March 31. Shares for $335,630 were sold by Carey Thomas D.. $126,925 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by Doyle James Edward.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on April, 26 after the close. They expect $-0.39 earnings per share, down 21.88% or $0.07 from last year’s $-0.32 per share. After $-0.18 actual earnings per share reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 116.67% negative EPS growth.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *